Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. provides health care services that facilitate outpatient care for durable medical equipment manufacturers and health care providers. News for INFU commonly covers financial results, segment trends and operating updates across Patient Services and Device Solutions, including oncology, pain management, wound therapy, direct payer rentals, pump and consumable sales, and biomedical services and repair.
Company updates also address revenue cycle management, payer-network and billing efficiency initiatives, relationships with DME manufacturers, contract economics, margin performance, cash flow, guidance and management presentations at investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a national distribution agreement with Genadyne Biotechnologies, enhancing its portfolio in negative pressure wound therapy (NPWT). InfuSystem will distribute Genadyne’s complete line of wound care products, including the advanced XLR8 Plus NPWT Pump and XLR8 Dressing Kit with Silver. This partnership aims to address supply chain challenges and provide diverse wound care solutions, ultimately improving patient outcomes and reducing healthcare costs. InfuSystem emphasizes its commitment to facilitating outpatient care and enhancing service delivery in the durable medical equipment sector.
InfuSystem Holdings, Inc. (NYSE American: INFU) reported record net revenues of $109.9 million for 2022, marking a 7% increase from 2021. The fourth quarter net revenues reached $28.8 million, a 9% year-over-year increase. Key segments include Integrated Therapy Services (ITS) with $68.9 million and Durable Medical Equipment (DME) at $41.0 million, growing 5% and 12% respectively. Adjusted EBITDA for 2022 was $20.7 million, down 14%. The company projects 2023 revenue growth of 8% to 10% with an Adjusted EBITDA margin over 19%. Management remains optimistic about strategic partnerships and growth in pain management services.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced it will release preliminary fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. A conference call will be held on the same day at 9:00 a.m. Eastern Time to discuss these results. The company operates through two platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services), providing comprehensive outpatient care. InfuSystem ensures local client support through its Centers of Excellence across several states and Ontario, Canada, enhancing its service delivery and operational efficiencies.